Oragenics, Inc.
ONP-002
mild traumatic brain injury (mTBI)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on ONP-002 for mild traumatic brain injury (mTBI) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“We expect that findings will support its planned investigational new drug (IND) application submission to the FDA for further clinical trials in the U.S.”